152 related articles for article (PubMed ID: 20510151)
21. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
Huang HC; Klein PS
Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
[TBL] [Abstract][Full Text] [Related]
22. Glycogen synthase kinase-3beta is associated with Parkinson's disease.
Nagao M; Hayashi H
Neurosci Lett; 2009 Jan; 449(2):103-7. PubMed ID: 19007860
[TBL] [Abstract][Full Text] [Related]
23. Association of glycogen synthase kinase-3β with Parkinson's disease (review).
Li DW; Liu ZQ; Chen W; Yao M; Li GR
Mol Med Rep; 2014 Jun; 9(6):2043-50. PubMed ID: 24681994
[TBL] [Abstract][Full Text] [Related]
24. Activation of PP2A-like phosphatase and modulation of tau phosphorylation accompany stress-induced apoptosis in cultured oligodendrocytes.
Goldbaum O; Richter-Landsberg C
Glia; 2002 Dec; 40(3):271-82. PubMed ID: 12420308
[TBL] [Abstract][Full Text] [Related]
25. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation.
Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A
Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881
[TBL] [Abstract][Full Text] [Related]
26. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
28. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A; Oddo S; Tran LX; LaFerla FM
Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
[TBL] [Abstract][Full Text] [Related]
29. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases.
Mazanetz MP; Fischer PM
Nat Rev Drug Discov; 2007 Jun; 6(6):464-79. PubMed ID: 17541419
[TBL] [Abstract][Full Text] [Related]
30. New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases.
Wang C; Cui Y; Xu T; Zhou Y; Yang R; Wang T
Biochem Pharmacol; 2023 Dec; 218():115923. PubMed ID: 37981175
[TBL] [Abstract][Full Text] [Related]
31. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
32. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.
Ma QL; Lim GP; Harris-White ME; Yang F; Ambegaokar SS; Ubeda OJ; Glabe CG; Teter B; Frautschy SA; Cole GM
J Neurosci Res; 2006 Feb; 83(3):374-84. PubMed ID: 16385556
[TBL] [Abstract][Full Text] [Related]
33. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
34. Glycogen synthase kinase-3beta and the p25 activator of cyclin dependent kinase 5 increase pausing of mitochondria in neurons.
Morel M; Authelet M; Dedecker R; Brion JP
Neuroscience; 2010 Jun; 167(4):1044-56. PubMed ID: 20211702
[TBL] [Abstract][Full Text] [Related]
35. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
[TBL] [Abstract][Full Text] [Related]
36. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation.
Resende R; Ferreiro E; Pereira C; Oliveira CR
J Neurosci Res; 2008 Jul; 86(9):2091-9. PubMed ID: 18335524
[TBL] [Abstract][Full Text] [Related]
37. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
38. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance.
Balaraman Y; Limaye AR; Levey AI; Srinivasan S
Cell Mol Life Sci; 2006 Jun; 63(11):1226-35. PubMed ID: 16568235
[TBL] [Abstract][Full Text] [Related]
39. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?
Martinez A; Perez DI
J Alzheimers Dis; 2008 Oct; 15(2):181-91. PubMed ID: 18953107
[TBL] [Abstract][Full Text] [Related]
40. Protein folding and misfolding in the neurodegenerative disorders: a review.
Bolshette NB; Thakur KK; Bidkar AP; Trandafir C; Kumar P; Gogoi R
Rev Neurol (Paris); 2014 Mar; 170(3):151-61. PubMed ID: 24613386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
